Icogenex is a Seattle-based, privately held company identifying and developing therapeutic compounds for the treatment of human diseases.
In pursuit of this goal, Icogenex has developed ICOCEPTTM, a technologically advanced high through-put screening methodology that has broad application in protein effector discovery.
Implementing this technology, we are working toward in-house drug development, as well as partnering with pharmaceutical companies in protein effector discovery programs.
Icogenex also has proven capability in expressing proteins from bacteria, yeast, or mammalian cells with a process called "IcoExpressTM". The Company has partnered or contracted on projects utilizing IcoExpress to assist other companies in expressing therapeutic proteins.
For more information, please contact us.